{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Reader CS"],"funding":["CRUK Core Facilities at Barts Cancer Institute, London","Cancer Research UK","Training Fellowship","Pancreatic Cancer UK","Medical Research Council","Pancreatic Cancer Research Fund","Wellcome Trust"],"pagination":["332-342"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6852434"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["249(3)"],"pubmed_abstract":["Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of less than 4% and desperately needs novel effective therapeutics. Integrin αvβ6 has been linked with poor prognosis in cancer but its potential as a target in PDAC remains unclear. We report that transcriptional expression analysis revealed that high levels of β6 mRNA correlated strongly with significantly poorer survival (n = 491 cases, p = 3.17 × 10<sup>-8</sup> ). In two separate cohorts, we showed that over 80% of PDACs expressed αvβ6 protein and that paired metastases retained αvβ6 expression. In vitro, integrin αvβ6 promoted PDAC cell growth, survival, migration, and invasion. Treatment of both αvβ6-positive human PDAC xenografts and transgenic mice bearing αvβ6-positive PDAC with the αvβ6 blocking antibody 264RAD, "],"journal":["The Journal of pathology"],"pubmed_title":["The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy."],"pmcid":["PMC6852434"],"funding_grant_id":["23526","RIF2015_A06_JAMIESON","17764","29996","G0800825","FLF2015_04_GLASGOW","25233","103721/Z/14/Z","11650","20409","C16420/A18066","21139"],"pubmed_authors":["Chelala C","Marshall JF","Keyse SM","Reader CS","Moore KM","Sansom OJ","Brentnall A","Lawlor R","Vallath S","Barry ST","Desai A","Scarpa A","Evans TJ","Haider S","Chang D","Jamieson NB","Biankin A","Morton JP","Kocher HM","Steele CW","Bailey P"],"additional_accession":[]},"is_claimable":false,"name":"The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy.","description":"Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of less than 4% and desperately needs novel effective therapeutics. Integrin αvβ6 has been linked with poor prognosis in cancer but its potential as a target in PDAC remains unclear. We report that transcriptional expression analysis revealed that high levels of β6 mRNA correlated strongly with significantly poorer survival (n = 491 cases, p = 3.17 × 10<sup>-8</sup> ). In two separate cohorts, we showed that over 80% of PDACs expressed αvβ6 protein and that paired metastases retained αvβ6 expression. In vitro, integrin αvβ6 promoted PDAC cell growth, survival, migration, and invasion. Treatment of both αvβ6-positive human PDAC xenografts and transgenic mice bearing αvβ6-positive PDAC with the αvβ6 blocking antibody 264RAD, ","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Nov","modification":"2025-04-04T08:26:57.767Z","creation":"2020-05-21T19:10:47Z"},"accession":"S-EPMC6852434","cross_references":{"pubmed":["31259422"],"doi":["10.1002/path.5320"]}}